Lung cancer • 4: Chemotherapy for non-small cell lung cancer: The end of the beginning

Thorax

Volumn 58, Issue 4, 2003, Pages 352-356

  Cullen, M ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; TENIPOSIDE; VINBLASTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG APPROVAL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; META ANALYSIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TUMOR GROWTH; LUNG TUMOR; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 0037382999     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.58.4.352     Document Type: Review

References (38)

1. Karnofsky DA, Abelman WH, Craver LF, et al. The use of nitrogen mustards in the palliative treatment of carcinoma (with particular reference to bronchogenic carcinoma). Cancer 1948;November:634-48.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials. BMJ 1995;311:899-909.
3. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality-of-life. J Clin Oncol 1999;17:3188-94.
4. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. J Natl Cancer Inst 1991;83:417-23.
5. Le Chevalier T, Arriagada R, Tarayre M. Significant effect of adjuvant therapy on survival in locally advanced non-small cell lung cancer. J Natl Cancer Inst 1992;84:58.
6. Sause WT, Kolesar P, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588 Southwest Oncology Group: Final results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. Chest 2000;117:358-64.
7. Cullen MH. "Best supportive care" has had its day. Lancet Oncol 2001;3:173-5.
8. Thongprasert S, Sanguanmitra P, Juthapen W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999;24:17-24.
9. Archer VR, Cullen MH. Palliative chemotherapy: no longer a contradiction in terms. The Oncologist 1999;4:470-7.
10. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced NSCLC: descriptive study based on scripted interviews. BMJ 1998;317:771-6.
11. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced NSCLC. Br J Cancer 1995;71:366-70.
12. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced NSCLC. J Natl Cancer Inst 1999;91:66-72.
13. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: a randomised trial with quality of life as the primary outcome. Br J Cancer 2000;83:447-53.
14. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomised trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum based chemotherapy. J Clin Oncol 2000;18:2095-103.
15. Rapp E, Pater J L, Willan A, et al. Chemotherapy can prolong survival in patients with advanced NSCLC: report of a Canadian multicentre randomised trial. J Clin Oncol 1988;6:633-41.
16. Bredin M, Corner J, Krishnasamy M, et al. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ 1999;318:901-4.
17. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small cell lung cancer. Ann Oncol 2001;12:1671-5.
18. Soria J-C, Brisgand D, Le Chevalier T. Do all patients with advanced non-small cell lung cancer benefit from cisplatin-based combination therapy. Ann Oncol 2001;12:1667-70.
19. Kelly K, Crowley J, Bunn PA, et al. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1999;18:461a.
20. Johnson DH, Zhu J, Schiller J, et al. E1594: a randomized phase III trial in metastatic non-small cell lung cancer (NSCLC) - outcome of PS 2 patients: an Eastern Cooperative Group trial (ECOG). Proc Am Soc Clin Oncol 1999;18:461a.
21. National Institute for Clinical Excellence (NICE). Guidance on the use of docetaxel, paclitaxel, gemcitabine and vinorelbine for the treatment of non-small cell lung cancer. London: NICE, 2001.
22. Office of National Statistics. Cancer incidence data for England and Wales. London: The Stationery Office, 1992.
23. Northern and Yorkshire Cancer Registry and Information Service (NYCRIS). Cancer treatment policies and their effects on survival. Key sites study: lung report. NYCRIS, 1999.
24. Royal College of Physicians of London. Lung cancer audit: City Centre University Hospital. London: Clinical Effectiveness and Evaluation Unit, Royal College of Physicians, 1999.
25. Cullen MH. Guidance on the management of lung cancer issued by NICE and the demand for chemotherapy in NSCLC. In: Muers M, Thatcher N, Wells F, Miles A, eds. Key advances in the effective management of lung cancer. 2nd ed. London: Aesculapius Medical Press, 2002.
26. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994;330:153-8.
27. Roth J, Fossella F, Komaki R. A randomized trial comparing peri-operative chemotherapy and surgery with surgery alone in patients with resectable stage III non-small cell lung cancer. J Natl Cancer Inst 1994;86:673-80.
28. Bonomi P, Kim KM, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin. Results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000;18:623-31.
29. Giaccone G, Splinter TAW, Debruyne C, et al. A randomised study paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. J Clin Oncol 1998;16:2133-41.
30. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer: A randomised phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999;17:3522-30.
31. Danson S, Clemons M, Middleton M, et al. A randomised study of gemcitabine with carboplatin versus mitomycin, vinblastine and cisplatin (MVP) or mitomycin, ifosfamide and cisplatin (MIC) as first line chemotherapy in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 2001;20:322a.
32. Schiller JH, Harrington D, Sandler A, et al. A randomised phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000;19:1a.
33. Langer C, Leighton JC, Corals RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival anarysis. J Clin Oncol 1995;13:1860-70.
34. Fosella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 1995;13:645-51.
35. Fosella FV, DeVore R, Kerr RN, et al. Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 2000;18:2354-62.
36. Saloman DS, Brandt R, Fortunato C, et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
37. Nakagawa K, Yamamoto N, Kudoh S, et al. A phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with solid malignant tumours. Proc Am Soc Clin Oncol 2000;19:183a.
38. Bonomi P, Perez-Soler R, Chachoua A, et al. A phase II trial of epidermal growth factor recetor (EGFR) tyrosine kinase inhibitor (TKI) CP-358,774 following platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Presented at 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy, Amsterdam, November 2000. Clin Cancer Res 2000;6(Suppl):4544S.